Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666692 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00666692 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 7 participants.
The verdict
NCT00666692, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary purpose of this study is to examine the safety of volociximab (V) in combination with a standard treatment of carboplatin (C), paclitaxel (P), and bevacizumab (B) in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV) non-squamous non-small cell lung cancer (NSCLC).
Interventions
- DRUG M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666692
The ClinicalTrials.gov registry entry for NCT00666692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab is the first listed.
NCT00666692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00666692 about?
NCT00666692 is a clinical study titled "A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)". The primary purpose of this study is to examine the safety of volociximab (V) in combination with a standard treatment of carboplatin (C), paclitaxel (P), and bevacizumab (B) in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV) non-squamous non-small cell lung cancer (NSCL...
What is the current status of trial NCT00666692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2008-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00666692?
The interventions under investigation include: M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00666692?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.